Antibodies News and Research

RSS

UKRI funding could initiate clinical trial for Cambridge-developed DNA vaccine against SARS-CoV-2

A Cambridge-developed DNA vaccine candidate against SARS-CoV-2 could begin clinical trials in the UK in late autumn or early next year, thanks to a £1.9 million award from the UK government.

27 Aug 2020

Heat Biologics SARS-CoV-2 vaccine generates potent T cell response in pre-clinical trial

The COVID-19 pandemic is still creating economic and health-related impact over the world. A new study published on the preprint server bioRxiv in August 2020 shows that a gp96-Ig-secreting vaccine candidate based on the expression of full-length spike protein generates a potent T cell response.

26 Aug 2020

Study suggests memory B cells persist following COVID-19 recovery

Researchers at Tel Aviv University in Israel have gained valuable insights into the serological and B cell response to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

26 Aug 2020

Exosomes: The cancer cell communication mechanism

Professor Deborah Goberdhan speaks to News-Medical about her team's latest research into cancer cells, and the mechanisms they use to communicate.

26 Aug 2020

BM32 vaccine against grass pollen allergy could be potential treatment for hepatitis B infection

Chronic hepatitis B infections represent a global health problem that could hitherto only be treated by chemotherapy.

26 Aug 2020

Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

A team of researchers from the Netherlands demonstrated that prophylactic treatment with a high dose of human convalescent plasma or by using concentrated monoclonal antibodies could protect against disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in an animal model. However, no protective effect was observed with a ten-fold lower dose of convalescent plasma. The results are currently available on the bioRxiv* preprint server.

25 Aug 2020

High SARS-CoV-2 antibody seroprevalence, low mortality at Austrian COVID-19 epicenter

Now, a new study reported on the preprint server medRxiv* in August 2020 describes a high seroprevalence in an Austrian ski resort, which is considered to be the source of the European outbreak.

25 Aug 2020

Researchers develop new technique to improve cancer treatments

An innovative technique to improve cancer treatments using tumour biopsies less than 30 minutes after they're taken has been developed at The University of Queensland.

25 Aug 2020

Study tracks the mutation rate of SARS-Cov-2 virus

Since COVID-19 began its menacing march across Wuhan, China, in December 2019, and then across the world, the SARS-CoV-2 virus has taken a "whatever works" strategy to ensure its replication and spread.

25 Aug 2020

Advances in Virus Epigenetics

Growing evidence shows viruses exploit epigenetic processes to control their life cycles but epigentic regulation of viral infections is not fully understood.

From Chromatrap® - Porvair Sciences Ltd 25 Aug 2020

Italy starts human trials of potential COVID-19 vaccine

Rome's Lazzaro Spallanzani Institute, a hospital specializing in infectious diseases will conduct trials on 90 volunteers in the coming weeks, joining a global effort to develop an immune response to the virus.

25 Aug 2020

COVID specific IgA monoclonal antibodies may provide effective immunity against coronavirus

A new study by researchers at MassBiologics of UMass Medical School published in Nature Communications suggests that COVID specific IgA monoclonal antibodies may provide effective immunity in the respiratory system against the novel coronavirus - a potentially critical feature of an effective vaccine.

25 Aug 2020

Scientists identify two markers of inflammation that predict severity of COVID-19 cases

Mount Sinai scientists have identified two markers of inflammation that reliably predict the severity of COVID-19 cases and likelihood of survival, providing a foundation for a diagnostic platform and therapeutic targets, according to a study published in Nature Medicine in August.

25 Aug 2020

UH to participate as study site for Pfizer and BioNTech's COVID-19 vaccine

University Hospitals announced today plans to participate as a study site for the Phase 2/3 global study sponsored by Pfizer Inc. and BioNTech SE of an investigational vaccine, BNT162b2, against SARS-CoV-2.

24 Aug 2020

Study reveals protective potential of all three major immunoglobulin isotypes against SARS-CoV-2

In a recent medRxiv preprint paper, researchers from Mount Sinai in New York showed that all three major immunoglobulin isotypes (IgM, IgG, and IgA) produced by our immune cells were capable of mediating neutralization of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, neutralization titers correlated much better with binding levels of IgM and IgA1 than IgG.

24 Aug 2020

Ferrets not susceptible to SARS-CoV-2 infection

A recent study by scientists at the Cummings School of Veterinary Medicine at Tufts University has revealed that ferrets are not susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection even if they are directly exposed to symptomatic coronavirus disease 2019 (COVID-19) patients for a prolonged time.

24 Aug 2020

New cancer vaccine is predicted to be more effective in human trials

Jefferson researchers developing a cancer vaccine to prevent recurrences of gastric, pancreatic, esophageal and colon cancers have added a component that would make the vaccine more effective.

24 Aug 2020

Bioinsider presents ‘Therapeutic Pipeline for COVID-19’ virtual meeting on September 17, 2020

Bioinsider, has opened registration for its upcoming virtual meeting ‘Therapeutic Pipeline for COVID-19’ on September 17, 2020.

From Twist Bioscience 24 Aug 2020

FDA issues emergency use authorization for convalescent plasma in COVID-19

The FDA said that based on the scientific evidence available, it had released a decision memorandum that convalescent plasma may be useful in treating COVID-19 in hospitalized patients, and the known potential benefits of use outweigh the risks.

24 Aug 2020

Equine antibody preparation shows greater capacity to neutralize SARS-CoV-2 isolate than human convalescent plasma

A recent Brazilian study demonstrates that hyperimmune globulin formulations generated against the recombinant spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provide significantly high antibody titer with highly neutralizing capacity. The study is currently available on the bioRxiv preprint server.

23 Aug 2020

Antibodies News and Research

UKRI funding could initiate clinical trial for Cambridge-developed DNA vaccine against SARS-CoV-2

Heat Biologics SARS-CoV-2 vaccine generates potent T cell response in pre-clinical trial

Study suggests memory B cells persist following COVID-19 recovery

Exosomes: The cancer cell communication mechanism

BM32 vaccine against grass pollen allergy could be potential treatment for hepatitis B infection

Monoclonal antibodies may be a better choice than convalescent plasma for treating COVID-19

High SARS-CoV-2 antibody seroprevalence, low mortality at Austrian COVID-19 epicenter

Researchers develop new technique to improve cancer treatments

Study tracks the mutation rate of SARS-Cov-2 virus

Advances in Virus Epigenetics

Italy starts human trials of potential COVID-19 vaccine

COVID specific IgA monoclonal antibodies may provide effective immunity against coronavirus

Scientists identify two markers of inflammation that predict severity of COVID-19 cases

UH to participate as study site for Pfizer and BioNTech's COVID-19 vaccine

Study reveals protective potential of all three major immunoglobulin isotypes against SARS-CoV-2

Ferrets not susceptible to SARS-CoV-2 infection

New cancer vaccine is predicted to be more effective in human trials

Bioinsider presents ‘Therapeutic Pipeline for COVID-19’ virtual meeting on September 17, 2020

FDA issues emergency use authorization for convalescent plasma in COVID-19

Equine antibody preparation shows greater capacity to neutralize SARS-CoV-2 isolate than human convalescent plasma

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo